PROFITEN SYRUP Israel - engelsk - Ministry of Health

profiten syrup

padagis israel pharmaceuticals ltd, israel - ketotifen as fumarate - syrup - ketotifen as fumarate 1 mg / 5 ml - other antihistamines for systemic use - prophylactic treatment of bronchial asthma. symptomatic treatment of allergic conditions including bronchitis, rhinitis, hay fever and urticaria.

PENTASA ENEMA Israel - engelsk - Ministry of Health

pentasa enema

ferring pharmaceuticals ltd - mesalazine - enema - mesalazine 1 g / 100 ml - aminosalicylic acid and similar agents - ulcerative colitis - chron's disease

DESLORATADINE 0.5 Mg/Ml Oral Solution Irland - engelsk - HPRA (Health Products Regulatory Authority)

desloratadine 0.5 mg/ml oral solution

rosemont pharmaceuticals ltd - desloratidine - oral solution - 0.5 mg/ml - other antihistamines for systemic use - antihistamines – h1 antagonist - it is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with: allergic rhinitis, urticaria

Ethambutol 400 mg Tablets Storbritannien - engelsk - myHealthbox

ethambutol 400 mg tablets

peckforton pharmaceuticals ltd - ethambutol hydrochloride - film-coated tablet - 400 mg - antimycobacterial - it is indicated for the primary treatment and re-treatment of tuberculosis and for prophylaxis in cases of inactive tuberculosis or large-tuberculinpositive reaction

Ethambutol 100 mg Tablets Storbritannien - engelsk - myHealthbox

ethambutol 100 mg tablets

peckforton pharmaceuticals ltd - ethambutol hydrochloride - film-coated tablet - 100 mg - antimycobacterial - it is used for the primary treatment and re-treatment of tuberculosis and for prophylaxis in cases of inactive tuberculosis or large-tuberculinpositive reaction.

Rivastigmine Rosemont 2mg/ml Oral Solution Storbritannien - engelsk - myHealthbox

rivastigmine rosemont 2mg/ml oral solution

rosemont pharmaceuticals ltd - rivastigmine hydrogen tartrate - oral solution - 2mg for ml - psychoanaleptics, anticholinesterases - symptomatic treatment of mild to moderately severe alzheimer's dementia; symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

Amlodipine 2mg/ml Oral Solution Storbritannien - engelsk - myHealthbox

amlodipine 2mg/ml oral solution

rosemont pharmaceuticals ltd - amlodipine - oral solution - 2 mg/ml - calcium channel blockers, selective calcium channel blockers with mainly vascular effects - hypertension; chronic stable angina pectoris; vasospastic (prinzmetal's) angina

Amlodipine 1mg/ml Oral Solution Storbritannien - engelsk - myHealthbox

amlodipine 1mg/ml oral solution

rosemont pharmaceuticals ltd - amlodipine - oral solution - 1mg/ml - calcium channel blockers, selective calcium channel blockers with mainly vascular effects - hypertension; chronic stable angina pectoris; vasospastic (prinzmetal's) angina

METHOTREXATE Irland - engelsk - HPRA (Health Products Regulatory Authority)

methotrexate

rosemont pharmaceuticals ltd - methotrexate disodium - oral solution - 2 mg/ml - methotrexate - antineoplastic and immunomodulating agents, antimetabolites, folic acid analogues - it is indicated in the following oncological indications: the maintenance treatment of acute lymphocytic leukaemia (all) in children and adults; the treatment of malignant trophoblastic tumours and for the treatment of severe active rheumatoid arthritis in adults and the treatment of severe forms of psoriasis vulgaris including chronic plaque psoriasis, erythrodermic psoriasis, psoriatic arthritis and pustular psoriasis which are not responsive to other conventional therapies such as phototherapy, puva and retinoids.

Risperidone 1mg/ml Oral Solution Storbritannien - engelsk - myHealthbox

risperidone 1mg/ml oral solution

rosemont pharmaceuticals ltd - risperidone - oral solution - 1mg/ml - other antipsychotics - it is indicated for the treatment of schizophrenia; for the treatment of moderate to severe manic episodes associated with bipolar disorders; for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer's dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others.; for the short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation diagnosed according to dsm-iv criteria, in whom the severity of aggressive or other disruptive behaviours require pharmacologic treatment.